Announced details
Surgical field; open rectal resection (as stated in the paper title)
The counterparty published the research paper on the domestic clinical trial of a product developed by the Company. Capital and personnel relationships: Not disclosed.
Location: Chuo-ku, Tokyo; President: Mano Hiroyuki (間野 博行). A national research and development agency that published the research paper.
DOI：10.1001/jamasurg.2026.3416
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
JAMA Surgery
National Cancer Center Japan website
| Item | Details |
|---|---|
| Names of Products / Services Covered | SI-449 (CS Barrier) |
| Counterparty | National Cancer Center |
| Counterparty overview | Location: Chuo-ku, Tokyo; President: Mano Hiroyuki (間野 博行). A national research and development agency that published the research paper. |
| Relationship with the Company | The counterparty published the research paper on the domestic clinical trial of a product developed by the Company. Capital and personnel relationships: Not disclosed. |
| Applicable area | Surgical field; open rectal resection (as stated in the paper title) |
| Registration number and expiry date | DOI：10.1001/jamasurg.2026.3416 |
| Source | JAMA Surgery, National Cancer Center Japan website |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because research findings on the efficacy and safety of SI-449 from the domestic clinical trial were published as a research paper.